Cargando…

Association of Neurodevelopmental Outcomes With Environmental Exposure to Cyclohexanone During Neonatal Congenital Cardiac Operations: A Secondary Analysis of a Randomized Clinical Trial

IMPORTANCE: Cyclohexanone is an industrial solvent used as a coupling agent in medical plastics. Perioperative exposure to cyclohexanone could play a role in lower scores on measures of neurodevelopmental outcomes after neonatal cardiac operations. OBJECTIVE: To examine the presence and association...

Descripción completa

Detalles Bibliográficos
Autores principales: Everett, Allen D., Buckley, Jessie P., Ellis, Greg, Yang, Jun, Graham, David, Griffiths, Megan, Bembea, Melania, Graham, Eric M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203603/
https://www.ncbi.nlm.nih.gov/pubmed/32374395
http://dx.doi.org/10.1001/jamanetworkopen.2020.4070
_version_ 1783529901295403008
author Everett, Allen D.
Buckley, Jessie P.
Ellis, Greg
Yang, Jun
Graham, David
Griffiths, Megan
Bembea, Melania
Graham, Eric M.
author_facet Everett, Allen D.
Buckley, Jessie P.
Ellis, Greg
Yang, Jun
Graham, David
Griffiths, Megan
Bembea, Melania
Graham, Eric M.
author_sort Everett, Allen D.
collection PubMed
description IMPORTANCE: Cyclohexanone is an industrial solvent used as a coupling agent in medical plastics. Perioperative exposure to cyclohexanone could play a role in lower scores on measures of neurodevelopmental outcomes after neonatal cardiac operations. OBJECTIVE: To examine the presence and association of serum cyclohexanone level with neonatal cardiac operations and neurodevelopmental outcomes. DESIGN, SETTING, AND PARTICIPANTS: This ad hoc secondary analysis used data from the Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass randomized clinical trial. The cohort included neonates younger than 31 days and with at least 37 weeks postgestational age at surgical treatment who were enrolled at a single center between June 1, 2012, and October 31, 2016, and who had completed a neurodevelopmental assessment at age 12 months. Data were analyzed from July 8 to August 20, 2019. EXPOSURES: Serum cyclohexanone and its metabolites were measured preoperatively (prior to skin incision), postoperatively (immediately after the surgical procedure was completed), and 12 hours postoperatively. Cyclohexanone and the molar sum of its metabolites were examined at each point and as a geometric mean of all 3 points. MAIN OUTCOMES AND MEASURES: Neurodevelopment was assessed at age 12 months with the Bayley Scales of Infant and Toddler Development III, assessing cognitive, language, and motor function composite scores standardized to a population mean (SD) of 100 (15). Linear regression models were used to determine covariate-adjusted differences in 12-month cognitive, language, and motor composite scores per interquartile range increase in cyclohexanone level or summed metabolite molar concentrations. RESULTS: Among 85 included neonates, mean (SD) age at surgical treatment was 9.7 (5.3) days, 49 (58%) were boys, and 54 (64%) underwent corrective repair. Mean (SD) Bayley Scales of Infant and Toddler Development III composite scores were 108.2 (12.2) for cognitive function, 104.7 (11.0) for language function, and 94.7 (15.7) for motor function. Median (interquartile range) cyclohexanone levels increased approximately 3-fold from immediately prior to surgical treatment to immediately after surgical treatment (572 [389-974] vs 1744 [1469-2291] μg/L; P = .001). In adjusted analyses, higher geometric mean cyclohexanone levels were associated with significantly lower composite scores for cognitive (−4.23; 95% CI, −7.39 to −1.06; P = .01) and language (−3.65; 95% CI, −6.41 to −0.88; P = .01) function. The difference in composite scores for motor function among infants with higher geometric mean cyclohexanone levels was not statistically significant(−3.93, 95% CI: −8.19 to 0.33, P = .07). CONCLUSIONS AND RELEVANCE: The findings of this secondary analysis of a randomized clinical trial suggest that infants who underwent neonatal cardiac surgical treatment with cardiopulmonary bypass had substantial cyclohexanone levels, which were associated with adverse neurodevelopmental function at age 12 months. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01579513
format Online
Article
Text
id pubmed-7203603
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-72036032020-05-07 Association of Neurodevelopmental Outcomes With Environmental Exposure to Cyclohexanone During Neonatal Congenital Cardiac Operations: A Secondary Analysis of a Randomized Clinical Trial Everett, Allen D. Buckley, Jessie P. Ellis, Greg Yang, Jun Graham, David Griffiths, Megan Bembea, Melania Graham, Eric M. JAMA Netw Open Original Investigation IMPORTANCE: Cyclohexanone is an industrial solvent used as a coupling agent in medical plastics. Perioperative exposure to cyclohexanone could play a role in lower scores on measures of neurodevelopmental outcomes after neonatal cardiac operations. OBJECTIVE: To examine the presence and association of serum cyclohexanone level with neonatal cardiac operations and neurodevelopmental outcomes. DESIGN, SETTING, AND PARTICIPANTS: This ad hoc secondary analysis used data from the Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass randomized clinical trial. The cohort included neonates younger than 31 days and with at least 37 weeks postgestational age at surgical treatment who were enrolled at a single center between June 1, 2012, and October 31, 2016, and who had completed a neurodevelopmental assessment at age 12 months. Data were analyzed from July 8 to August 20, 2019. EXPOSURES: Serum cyclohexanone and its metabolites were measured preoperatively (prior to skin incision), postoperatively (immediately after the surgical procedure was completed), and 12 hours postoperatively. Cyclohexanone and the molar sum of its metabolites were examined at each point and as a geometric mean of all 3 points. MAIN OUTCOMES AND MEASURES: Neurodevelopment was assessed at age 12 months with the Bayley Scales of Infant and Toddler Development III, assessing cognitive, language, and motor function composite scores standardized to a population mean (SD) of 100 (15). Linear regression models were used to determine covariate-adjusted differences in 12-month cognitive, language, and motor composite scores per interquartile range increase in cyclohexanone level or summed metabolite molar concentrations. RESULTS: Among 85 included neonates, mean (SD) age at surgical treatment was 9.7 (5.3) days, 49 (58%) were boys, and 54 (64%) underwent corrective repair. Mean (SD) Bayley Scales of Infant and Toddler Development III composite scores were 108.2 (12.2) for cognitive function, 104.7 (11.0) for language function, and 94.7 (15.7) for motor function. Median (interquartile range) cyclohexanone levels increased approximately 3-fold from immediately prior to surgical treatment to immediately after surgical treatment (572 [389-974] vs 1744 [1469-2291] μg/L; P = .001). In adjusted analyses, higher geometric mean cyclohexanone levels were associated with significantly lower composite scores for cognitive (−4.23; 95% CI, −7.39 to −1.06; P = .01) and language (−3.65; 95% CI, −6.41 to −0.88; P = .01) function. The difference in composite scores for motor function among infants with higher geometric mean cyclohexanone levels was not statistically significant(−3.93, 95% CI: −8.19 to 0.33, P = .07). CONCLUSIONS AND RELEVANCE: The findings of this secondary analysis of a randomized clinical trial suggest that infants who underwent neonatal cardiac surgical treatment with cardiopulmonary bypass had substantial cyclohexanone levels, which were associated with adverse neurodevelopmental function at age 12 months. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01579513 American Medical Association 2020-05-06 /pmc/articles/PMC7203603/ /pubmed/32374395 http://dx.doi.org/10.1001/jamanetworkopen.2020.4070 Text en Copyright 2020 Everett AD et al. JAMA Network Open. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Everett, Allen D.
Buckley, Jessie P.
Ellis, Greg
Yang, Jun
Graham, David
Griffiths, Megan
Bembea, Melania
Graham, Eric M.
Association of Neurodevelopmental Outcomes With Environmental Exposure to Cyclohexanone During Neonatal Congenital Cardiac Operations: A Secondary Analysis of a Randomized Clinical Trial
title Association of Neurodevelopmental Outcomes With Environmental Exposure to Cyclohexanone During Neonatal Congenital Cardiac Operations: A Secondary Analysis of a Randomized Clinical Trial
title_full Association of Neurodevelopmental Outcomes With Environmental Exposure to Cyclohexanone During Neonatal Congenital Cardiac Operations: A Secondary Analysis of a Randomized Clinical Trial
title_fullStr Association of Neurodevelopmental Outcomes With Environmental Exposure to Cyclohexanone During Neonatal Congenital Cardiac Operations: A Secondary Analysis of a Randomized Clinical Trial
title_full_unstemmed Association of Neurodevelopmental Outcomes With Environmental Exposure to Cyclohexanone During Neonatal Congenital Cardiac Operations: A Secondary Analysis of a Randomized Clinical Trial
title_short Association of Neurodevelopmental Outcomes With Environmental Exposure to Cyclohexanone During Neonatal Congenital Cardiac Operations: A Secondary Analysis of a Randomized Clinical Trial
title_sort association of neurodevelopmental outcomes with environmental exposure to cyclohexanone during neonatal congenital cardiac operations: a secondary analysis of a randomized clinical trial
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203603/
https://www.ncbi.nlm.nih.gov/pubmed/32374395
http://dx.doi.org/10.1001/jamanetworkopen.2020.4070
work_keys_str_mv AT everettallend associationofneurodevelopmentaloutcomeswithenvironmentalexposuretocyclohexanoneduringneonatalcongenitalcardiacoperationsasecondaryanalysisofarandomizedclinicaltrial
AT buckleyjessiep associationofneurodevelopmentaloutcomeswithenvironmentalexposuretocyclohexanoneduringneonatalcongenitalcardiacoperationsasecondaryanalysisofarandomizedclinicaltrial
AT ellisgreg associationofneurodevelopmentaloutcomeswithenvironmentalexposuretocyclohexanoneduringneonatalcongenitalcardiacoperationsasecondaryanalysisofarandomizedclinicaltrial
AT yangjun associationofneurodevelopmentaloutcomeswithenvironmentalexposuretocyclohexanoneduringneonatalcongenitalcardiacoperationsasecondaryanalysisofarandomizedclinicaltrial
AT grahamdavid associationofneurodevelopmentaloutcomeswithenvironmentalexposuretocyclohexanoneduringneonatalcongenitalcardiacoperationsasecondaryanalysisofarandomizedclinicaltrial
AT griffithsmegan associationofneurodevelopmentaloutcomeswithenvironmentalexposuretocyclohexanoneduringneonatalcongenitalcardiacoperationsasecondaryanalysisofarandomizedclinicaltrial
AT bembeamelania associationofneurodevelopmentaloutcomeswithenvironmentalexposuretocyclohexanoneduringneonatalcongenitalcardiacoperationsasecondaryanalysisofarandomizedclinicaltrial
AT grahamericm associationofneurodevelopmentaloutcomeswithenvironmentalexposuretocyclohexanoneduringneonatalcongenitalcardiacoperationsasecondaryanalysisofarandomizedclinicaltrial